Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Halozyme

Dow Jones Futures Fuel New Market Rally On Bank Of Japan; Nvidia Partner Super Micro Dives

Futures added to a new market rally attempt thanks to Bank of Japan comments. Nvidia partner Super Micro was a big earnings loser.

Investors Business Daily

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

Halozyme Therapeutics obliterated second-quarter expectations, and the No. 1 biotech stock jumped early Wednesday.

Investors Business Daily

3 Biotech Stocks Showing Promising Returns for October

3 Biotech Stocks Showing Promising Returns for October

Technological advancements and the growing investment in developing healthcare infrastructures are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR). Read more.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme

Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday.

Investors Business Daily

Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review

The stock market rally soared this week on a tame CPI inflation report. Bitcoin hit a two-year low while Meta and Tesla were in focus.

Investors Business Daily

The Blockbuster Potential That Sent IBD Stock Of The Day Halozyme Into A Breakout

IBD Stock Of The Day Halozyme is entering a new wave of development — leading HALO stock to surge into a breakout Wednesday.

Investors Business Daily

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

inkl

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures Fall After Techs Lead Stock Market Rebound; Investors See End To Fed Rate Hikes

Dow Jones Futures Fall After Techs Lead Stock Market Rebound; Investors See End To Fed Rate Hikes

Apple and other techs led a big rally off morning lows as oil prices and bond yields dived. Markets see Fed rate hikes ending this year.

Investors Business Daily

Why Antares Pharma Stock Is Soaring Today

Why Antares Pharma Stock Is Soaring Today

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at

Biotech Feeding Spree As GSK, Halozyme Announce Nearly $3 Billion In Deals

Biotech Feeding Spree As GSK, Halozyme Announce Nearly $3 Billion In Deals

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.

Investors Business Daily

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity

Halozyme Therapeutics Inc (NASDAQ:HALO) will acquire Antares Pharma Inc (NASDAQ:ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027. Antares' suite of FDA-approved and partner products utilizing…

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Johnson & Johnson's (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab. According to Janssen, Genmab must share…

Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact

Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact

Halozyme Therapeutics Inc (NASDAQ: HALO) has

Get all your
news in one place.

100’s of premium titles.
One news app.

Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth

Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 r

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

262,811 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play